New Products - Tivicay

Tivicay (dolutegravir (as dolutegravir sodium)) is an integrase inhibitor active against human immunodeficiency virus (HIV). Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Tivicay is indicated for the treatment of HIV infection in combination with other antiretroviral agents in adults and children over 12 years of age and weighing 40 kg or more. It is contraindicated in combination with dofetilide. Tivicay is available as 50 mg tablets in bottles of 30's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.